1CM
ADPT icon

1492 Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

1492 Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.21M Buy
382,840
+101,744
+36% +$1.56M 2.42% 7
2026
Q1 		$3.9M Buy
281,096
+189,721
+208% +$3.02M 1.49% 22
2025
Q4 		$1.48M Buy
+91,375
New +$1.49M 0.57% 55

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

1492 Capital Management's ADPT Position: Q2 2026 in Review

1492 Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 36% in Q2 2026, buying an estimated $1.56M and bringing the position to 382,840 shares worth $8.21M. The position accounts for 2.42% of the portfolio, ranked #7.

1492 Capital Management first reported a position in ADPT in Q4 2025 and has held it in 3 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • 1492 Capital Management held 382,840 shares of Adaptive Biotechnologies worth $8.21M as of Q2 2026.
  • 1492 Capital Management bought 101,744 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.56M.
  • Adaptive Biotechnologies made up 2.42% of 1492 Capital Management's portfolio in Q2 2026, its #7 holding.
  • 1492 Capital Management first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 3 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.